<DOC>
	<DOCNO>NCT00786058</DOCNO>
	<brief_summary>The purpose study compare best supportive care plus oxaliplatin/ folinic acid/ 5-FU versus best supportive alone patient gemcitabine refractory pancreatic cancer .</brief_summary>
	<brief_title>A Phase III Second Line Trial Advanced Pancreatic Cancer CONKO 003</brief_title>
	<detailed_description>Gemcitabine ( G ) give progressive disease ( PD ) still standard therapy patient advance pancreatic cancer . No standard secondline regimen available PD . Best supportive care ( BSC ) main option patient . Our phase II study ( Pelzer et al , ASCO 2002 ) show activity OFF ( Oxaliplatin/Folinic Acid/5-FU ) regimen . To confirm data start multicenter phase III study examine OFF vs. BSC alone . 165 patient need study . Following CT/ MRT confirm PD patient randomize . Stratification include duration firstline therapy , Karnofsky Performance Status ( KPS ) tumor stage . OFF ( outpatient regimen ) : 5-FU 2g/m² ( 24h ) /FA 200 mg/m² ( 30min ) d1 , d8 , d15 , d22 , additional Oxaliplatin 85mg/m² ( 2h ) day 8 22 . Rest day 23 42 .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Patients histologically cytologically confirm metastatic pancreatic adenocarcinoma progress first line gemcitabine therapy eligible inclusion study . Other inclusion criterion : Age &gt; 18 year Karnofsky performance status &gt; 70 % Bidimensionally measurable reference lesion , adequate laboratory value hematology ( white blood cell [ WBC ] count &gt; 3.5´109/L , platelet count &gt; 100´109/L ) , renal function ( creatine clearance &gt; 30 ml/min ) hepatic function ( aspartate aminotransferase [ AST ] alanine aminotransferase [ ALT ] &lt; 2.5 ´ upper normal limit [ UNL ] case liver metastasis &lt; 5 x UNL ) As well control pain Patients exclude study severe concurrent medical condition interfering plan therapy , serious cardiac disease , sensory/ motor neuropathy &gt; grade 2 previous current malignancy origin ; besides , pregnant lactate woman exclude . All patient provide write informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>refractory pancreatic cancer</keyword>
	<keyword>gemcitabine</keyword>
	<keyword>phase III</keyword>
	<keyword>second line</keyword>
</DOC>